Ipca Laboratories is currently trading at Rs. 455.70, down by 57.45 points or 11.20% from its previous closing of Rs. 513.15 on the BSE.
The scrip opened at Rs. 464.00 and has touched a high and low of Rs. 484.40 and Rs. 437.00 respectively. So far 5,74,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 656.00 on 05-Apr-2017 and a 52 week low of Rs. 435.00 on 24-Jun-2016.
Last one week high and low of the scrip stood at Rs. 527.85 and Rs. 437.00 respectively. The current market cap of the company is Rs. 5,753.00 crore.
The promoters holding in the company stood at 46.13%, while Institutions and Non-Institutions held 37.25% and 16.62% respectively.
Almost all drugs manufactured by Ipca Laboratories at its facilities at Pithampur, Silvassa and Ratlam have been banned from the US market by US Food and Drug Administration (USFDA). The ban of all drugs will continue until the company can demonstrate that the drugs manufactured sites and intended for the US market are in compliance with Current Good Manufacturing Practice (CGMP).
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1850.40 |
| Dr. Reddys Lab | 1310.50 |
| Cipla | 1365.25 |
| Zydus Lifesciences | 939.10 |
| Lupin | 2442.35 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: